|
James F. List describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo T2DM: DAPAGLIFLOZIN, METFORMIN XR, OR BOTH In treatment-naïve patients with type 2 diabetes (T2D), initial combination therapy with dapagliflozin + extended-release metformin (MET XR) resulted in significant improvements in glycaemic and weight outcomes. Dapagliflozin + MET XR provided superior glycaemic benefits to monotherapy with either agent. The combination treatment was generally well tolerated. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación Multiple sites in North America, Latin America, Europe, Asia. Address is not provided below, because there was no one principal institution., N/A, N/A, United States  Authors' Report Crónica del Autor Bibliographic references Referencias bibliográficas 1. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs. 2008;68(15):2131-2162. 2. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491-497. 3. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515-529. 4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203. 5. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223-2233. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Dapaglifozin, Metformin XR, or Both: Initial Pharmacotherapy for Type 2 Diabetes, a Randomised Controlled Trial Author / Autor James F. List1, James F. List2 2 Vice President, Full Developme Access to the original source International Journal of Clinical Practice Article URL: / URL del artículo: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1742-1241 URL of Abstract: / URL del abstract: http://www.ncbi.nlm.nih.gov/pubmed/22413962 URL of Abstract page in Medline: / URL del abstract en Medline: http://www.ncbi.nlm.nih.gov/pubmed/22413962 siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
||||||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
